FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma By Ogkologos - February 25, 2026 48 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC MOST POPULAR Woman Has Unnecessary Double Mastectomy and Narrowly Avoids Hysterectomy After Bad... March 27, 2019 Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities March 6, 2026 Resource Round-Up: Let’s Win Pancreatic Cancer May 23, 2023 Gift Giving During a Pandemic December 3, 2020 Load more HOT NEWS 7 images that defined cancer policy in 2022 Listening to Patient Narratives Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer How to Improve Cancer-Related Fatigue Using Exercise: Expert Perspectives
